(Q48391442)

English

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study

scientific article published in November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Giuseppe Procopio

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Antonia Martinetti

4

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Giacomo Cartenì

10

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Filippo de Braud

11

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

author name string

Emilio Bajetta

1

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Laura Catena

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Sara De Dosso

5

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Sergio Ricci

6

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Alberto S Lecchi

7

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Paolo F Boscani

8

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Stefano Iacobelli

9

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Paola Loli

12

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Andreas Tartaglia

13

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Roberto Bajetta

14

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Leonardo Ferrari

15

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

language of work or name

0 references

publication date

1 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

107

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

10

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

2474-2481

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

Carcinoid tumour

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

[111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Slow-release lanreotide treatment in endocrine gastrointestinal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22272

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22272

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/17054107

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48391442&oldid=2196664427"